Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01096342 · OUTCOME

Progression-free Survival

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2014-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Time from registration to progression or death due to any cause, assessed up to 3 years

What was measured

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.

Analysis population: All 15 evaluable participants were analyzed for Progression-Free Survival.

Groups in this outcome

Phase II

Participants were accrued at 50 mg/m\^2 dose level after December 30, 2009 addendum. Participants to receive 50 mg/m\^2 dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase II15

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase II2.73Not reported0.695.52Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.69
        upper Limit
        5.52
        value
        2.73
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants were accrued at 50 mg/m\^2 dose level after December 30, 2009 addendum. Participants to receive 50 mg/m\^2 dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Phase II
param Type
MEDIAN
population Description
All 15 evaluable participants were analyzed for Progression-Free Survival.
reporting Status
POSTED
time Frame
Time from registration to progression or death due to any cause, assessed up to 3 years
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice